Literature DB >> 12413771

TGF-beta1-mediated regulation of thymus and activation-regulated chemokine (TARC/CCL17) synthesis and secretion by HaCaT cells co-stimulated with TNF-alpha and IFN-gamma.

Xueyi Zheng1, Koichiro Nakamura, Michiko Tojo, Noritaka Oyama, Akiko Nishibu, Masataka Satoh, Takashi Kakinuma, Motoshi Wakugawa, Kunihiko Tamaki, Fumio Kaneko.   

Abstract

Thymus and activation-regulated chemokine (TARC/CCL17) contributes not only to the recruitment of leukocytes, but is also involved in immune disorders, such as atopic dermatitis (AD) and bronchial asthma. We have previously reported that the levels of TARC were high in patients with AD and that lesional epidermis were strongly immunoreactive for TARC. In this paper, the effects of transforming growth factor (TGF)-beta(1) on the expression of TARC/CCL17 were examined in HaCaT cells, a human keratinocytes (KCs) cell line, co-stimulated with TNF-alpha and IFN-gamma. We found that TGF-beta(1) down-regulated the TARC synthesis and secretion of HaCaT cells co-stimulated with TNF-alpha and IFN-gamma in a dose-dependent manner. TGF-beta(1) at a concentration of 10ng/ml maximally inhibited this secretion. Northern blot analysis showed a similar inhibitory effect of TGF-beta(1) on TARC mRNA expression by HaCaT cells. The TGF-beta(1)-induced down-regulation of TARC/CCL17 in HaCaT cells suggests that TGF-beta(1) might regulate the TARC-related inflammatory processes, which may be important for understanding the pathogenesis of allergic diseases. Copyright 2002 Elsevier Science Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12413771     DOI: 10.1016/s0923-1811(02)00071-3

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  3 in total

1.  Sorafenib inhibits ovarian cancer cell proliferation and mobility and induces radiosensitivity by targeting the tumor cell epithelial-mesenchymal transition.

Authors:  Chuntao Tian; Ying Liu; Lingfei Xue; Dong Zhang; Xiaotong Zhang; Jing Su; Jiaohong Chen; Xiangke Li; Liuxing Wang; Shunchang Jiao
Journal:  Open Life Sci       Date:  2022-06-15       Impact factor: 1.311

2.  IL-4 induces expression of TARC/CCL17 via two STAT6 binding sites.

Authors:  Gerald Wirnsberger; Daniel Hebenstreit; Gernot Posselt; Jutta Horejs-Hoeck; Albert Duschl
Journal:  Eur J Immunol       Date:  2006-07       Impact factor: 5.532

Review 3.  What does elevated TARC/CCL17 expression tell us about eosinophilic disorders?

Authors:  Julien Catherine; Florence Roufosse
Journal:  Semin Immunopathol       Date:  2021-05-19       Impact factor: 9.623

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.